Clinical Trial Update: Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating rituximab and bendamustine with or without brentuximab vedotin in CD30-positive diffuse large B-cell lymphoma and related B-cell lympho…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular B-cell Non-hodgkin Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Brentuximab vedotin (Brentuximab vedotin)
• Rituximab (rituximab)
• Seagen Inc.

Snippet

Sponsor: Seagen Inc. | Conditions: Diffuse Large B-cell Lymphoma Refractory, Follicular B-cell Non-Hodgkin's Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2018-10-16